GSK3β inhibitors showed positive improvement in animal models, but unfortunately failed in AD patients (Rippin & Eldar‐Finkelman, 2021; Arciniegas Ruiz & Eldar‐Finkelman, 2022). The gene discussed is GSK3B; the disease is Alzheimer disease.